| pubmed-article:8541532 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C0042960 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C1549078 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C0079459 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C1997894 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C0210630 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C0300926 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C0205307 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C1516698 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C1446911 | lld:lifeskim |
| pubmed-article:8541532 | lifeskim:mentions | umls-concept:C1554097 | lld:lifeskim |
| pubmed-article:8541532 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:8541532 | pubmed:dateCreated | 1996-2-13 | lld:pubmed |
| pubmed-article:8541532 | pubmed:abstractText | To define an optimal regimen for mobilizing and collecting peripheral blood progenitor cells (PBPC) for use in allogeneic transplantation, we evaluated the kinetics of mobilization by filgrastim (recombinant met-human granulocyte colony-stimulating factor [r-metHuG-CSF]) in normal volunteers. Filgrastim was injected subcutaneously for up to 10 days at a dose of 3 (n = 10), 5 (n = 5), or 10 micrograms/kg/d (n = 15). A subset of volunteers from each dose cohort underwent a 7L leukapheresis on study day 6 (after 5 days of filgrastim). Granulocyte-macrophage colony-forming cell (GM-CFC) numbers in the blood were maximal after 5 days of filgrastim; a broader peak was evident for CD34+ cells between days 4 and 6. The 95% confidence intervals (CI) for mean number of PBPC per milliliter of blood in the three dose cohorts overlapped on each study day. However, on the peak day, CD34+ cells were significantly higher in the 10 micrograms/kg/d cohort than in a pool of the 3 and 5 micrograms/kg/d cohorts. Mobilization was not significantly influenced by volunteer age or sex. Leukapheresis products obtained at the 10 micrograms/kg/d dose level contained a median GM-CFC number of 93 x 10(4)/kg (range, 50 x 10(4)/kg to 172 x 10(4)/kg). Collections from volunteers receiving lower doses of filgrastim contained a median GM-CFC number of 36 x 10(4)/kg (range, 5 x 10(4)/kg to 204 x 10(4)/kg). The measurement of CD34+ cells per milliliter of blood on the day of leukapheresis predicted the total yield of PBPC in the leukapheresis product (r = .87, P < .0001). Assuming a minimum GM-CFC requirement of 50 x 10(4)/kg (based on our experience with autologous PBPC transplantation), all seven leukapheresis products obtained at the 10 micrograms/kg/d dose level were potentially sufficient for allogeneic transplantation purposes. We conclude that in normal donors, filgrastim 10 micrograms/kg/d for 5 days with a single leukapheresis on the following day is a highly effective regimen for PBPC mobilization and collection. Further studies are required to determine whether PBPC collected with this regimen reliably produce rapid and sustained engraftment in allogeneic recipients. | lld:pubmed |
| pubmed-article:8541532 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8541532 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8541532 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8541532 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8541532 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8541532 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8541532 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8541532 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:8541532 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:8541532 | pubmed:author | pubmed-author:LaytonJ EJE | lld:pubmed |
| pubmed-article:8541532 | pubmed:author | pubmed-author:BoydA WAW | lld:pubmed |
| pubmed-article:8541532 | pubmed:author | pubmed-author:McGrathK MKM | lld:pubmed |
| pubmed-article:8541532 | pubmed:author | pubmed-author:HoughtonSS | lld:pubmed |
| pubmed-article:8541532 | pubmed:author | pubmed-author:RobertsA WAW | lld:pubmed |
| pubmed-article:8541532 | pubmed:author | pubmed-author:MaherDD | lld:pubmed |
| pubmed-article:8541532 | pubmed:author | pubmed-author:GriggA PAP | lld:pubmed |
| pubmed-article:8541532 | pubmed:author | pubmed-author:RaunowHH | lld:pubmed |
| pubmed-article:8541532 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8541532 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8541532 | pubmed:volume | 86 | lld:pubmed |
| pubmed-article:8541532 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8541532 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8541532 | pubmed:pagination | 4437-45 | lld:pubmed |
| pubmed-article:8541532 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8541532 | pubmed:meshHeading | pubmed-meshheading:8541532-... | lld:pubmed |
| pubmed-article:8541532 | pubmed:meshHeading | pubmed-meshheading:8541532-... | lld:pubmed |
| pubmed-article:8541532 | pubmed:meshHeading | pubmed-meshheading:8541532-... | lld:pubmed |
| pubmed-article:8541532 | pubmed:meshHeading | pubmed-meshheading:8541532-... | lld:pubmed |
| pubmed-article:8541532 | pubmed:meshHeading | pubmed-meshheading:8541532-... | lld:pubmed |
| pubmed-article:8541532 | pubmed:meshHeading | pubmed-meshheading:8541532-... | lld:pubmed |
| pubmed-article:8541532 | pubmed:meshHeading | pubmed-meshheading:8541532-... | lld:pubmed |
| pubmed-article:8541532 | pubmed:meshHeading | pubmed-meshheading:8541532-... | lld:pubmed |
| pubmed-article:8541532 | pubmed:meshHeading | pubmed-meshheading:8541532-... | lld:pubmed |
| pubmed-article:8541532 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8541532 | pubmed:articleTitle | Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. | lld:pubmed |
| pubmed-article:8541532 | pubmed:affiliation | Department of Clinical Hematology and Medical Oncology, Royal Melbourne Hospital, Victoria, Australia. | lld:pubmed |
| pubmed-article:8541532 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8541532 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8541532 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8541532 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8541532 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8541532 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8541532 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8541532 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8541532 | lld:pubmed |
